Wednesday, June 03, 2015 11:05:42 AM
launch (?) - December 2013: $184.00 ($135.89)
December 2013 - November 2014: $195.04 ($130.48)
"We increased our wholesale pricing 6% in December to a price of $195 for a bottle of 120 Vascepa capsules." - CC Q4 2013
"The wholesale price for 120 capsules or one-month supply of Vascepa is $195.04 compared to $198.50 for generic Lovaza and $229.75 for branded Lovaza." - CC Q1 2014
"The wholesale price for 120 capsules or one-month supply of Vascepa is $195.04 which is less than the price of the currently marketed generic Lovaza which is priced at $198.50 and considerably less than branded Lovaza at $229.75. A second generic Lovaza product was approved in June. It has a published wholesale price of $183.80, this product which is not yet being launched while its wholesale price is slightly lower than Vascepa is more expensive than Vascepa for most payers after adjustment for copayment and (inaudible) differences between the branded and generic product." - CC Q2 2014
November 2014 - March 2015 (?): $208.69 ($128.62)
"We increased the wholesale price for Vascepa by 7% in late November 2014. This increase which during 2015 is likely to be largely offset on a net price basis by rebates for expanding Tier 2 coverage continues to position the price of Vascepa at a level that is below the net price of generic Lovaza for most payors with of course the clinical differentiation that drove our Tier 2 coverage before generic Lovaza became available. ... Even though the recently launched Apotex version of generic is the third generic to market, the wholesale acquisition cost is at a premium to the second market entrant and is priced at $198.50 for a bottle of 120 capsules, this is equal to the first available generic Lovaza for which the price has not eroded since launching 10 months ago."
April 2015 (?) - : $221.00 ($135.89)
"Wholesale price $221 per month (120 capsules; daily does 4 capsules per day) ... Vascepa price at parity to generics of prior generation omega-3 on net basis for most payors" - Investor Presentation June 1, 2015
Recent AMRN News
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 12:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:31:21 PM
- Amarin Chairman & CEO Issue Letter to Shareholders • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM